topotecan/סרטן

הקישור נשמר בלוח

בחר סוג מיון

עמוד 1 מ 1446 תוצאות

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. METHODS Patients with stage IIIB or IV NSCLC with measurable disease in nonradiated fields were eligible. Other

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Based on previous experience, we combined topotecan with paclitaxel (weekly administration) in patients with non-small-cell lung cancer (NSCLC). Our primary objective was to determine the response rate and survival and our secondary objective, the safety of the regimen. METHODS From

Phase II study of oral topotecan in advanced non-small cell lung cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

This study was designed to assess the activity of oral topotecan (TPT) in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. Eligible patients had inoperable stage III or stage IV non-small cell lung cancer and were chemotherapy-naive. Other inclusion criteria

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Camptothecins are DNA topoisomerase I-directed anti-tumour drugs with a novel mechanism of action. Topotecan (TPT), a hydrophilic derivative of camptothecin, is currently undergoing phase II clinical trials in small-cell lung cancer (SCLC). Human SCLC OC-NYH cells were made more than 6-fold

Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Topotecan and vincristine were evaluated alone or in combination against 13 independent xenografts and 1 vincristine-resistant derivative, representing childhood neuroblastoma (n = 6), rhabdomyosarcoma (n = 5), or brain tumors (n = 3). Topotecan was given by i.v. bolus on a schedule found previously

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Topotecan, a novel topoisomerase-I inhibitor, is an active agent of second-line chemotherapy for extending the platinum-free interval (PFI) and improving the chances of a response to platinum in recurrent ovarian cancer patients. The aim of this study was to understand the molecular

Experience with independent radiological review during a topotecan trial in ovarian cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND The results of phase II clinical trials are usually based on response of tumours to new oncolytic agents as evidenced by radiological imaging techniques. In this trial, all claimed responders were reviewed at a specially convened meeting by the peer group of study investigators and a

Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Metronomic chemotherapy, combined with targeted antiangiogenic drugs, has demonstrated significant anticancer efficacy in various studies. Though, tumors do acquire resistance. Here, we have investigated the effect of prolonged therapy with oral metronomic topotecan and pazopanib on tumor behavior

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors. METHODS Patients aged ≥ 18 years with histologically

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent

Topotecan as first-line therapy for small cell lung cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Although current treatments for small-cell lung cancer (SCLC) yield objective response rates exceeding 50%, most patients relapse. Hence, research into the identification of novel agents and combinations that may improve therapy is ongoing. Topotecan, an established treatment for patients with

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Effective therapies with a low rate of side effects are warranted in the 2nd-line setting in ovarian cancer. Both topotecan and the alkylating agent treosulfan have demonstrated efficacy in this patient group and are broadly used in Germany. Therefore, we started a prospectively randomized

Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Platinum-based chemotherapy is considered standard treatment for advanced non-small-cell lung cancer (NSCLC). However, toxicity of most platinum-based regimens is substantial and requires close monitoring and supportive care. Over the past decade, paclitaxel, docetaxel, vinorelbine, gemcitabine,

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly haematologic. Since preclinical data

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy. METHODS Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology Group

קודם
1
2
3
4
5
6
...
96
97
הַבָּא

הצטרפו לדף הפייסבוק שלנו

Herbal & Natural Medicine

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע

עובד ב 55 שפות
מרפא צמחי מרפא מגובה על ידי מדע
זיהוי עשבי תיבול על ידי דימוי
מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
קרא פרסומים מדעיים הקשורים לחיפוש שלך
חפש עשבי מרפא על פי השפעותיהם
ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים

הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם